Stable Cell Lines for Inducible rAAV Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing recombinant adeno-associated virus (rAAV) virions are inefficient and expensive, leading to variable product quality and toxicity issues due to constitutive expression of AAV Rep and adenoviral helper proteins.
Innovation Solution
Development of stable mammalian cell lines capable of conditionally producing rAAV virions, where the production is inducible upon addition of a triggering agent and not dependent on the presence of a plasmid, ensuring homogenous virion populations and reduced toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If transient transfection of multiple plasmids is used to produce rAAV virions, then production capacity can be increased, but manufacturing efficiency decreases and production cost increases
Solution Approach 1:
The patent segments the rAAV production system into three separate stable cell lines, each expressing one component (Rep/Cap, helper proteins, or payload). This segmentation allows each cell line to be optimized independently and eliminates the need for simultaneous plasmid transfection, thereby improving manufacturing efficiency while maintaining high production capacity.
Solution Approach 2:
The patent implements preliminary action by establishing stable cell lines that permanently express the necessary components before production is needed. This eliminates the need for repeated transfection procedures and ensures consistent, high-level expression of all components, improving both efficiency and scalability.
2Quantity of substance
If transient transfection of multiple plasmids is used to produce rAAV virions, then production capacity can be increased, but product quality becomes variable
Solution Approach 1:
By segmenting the production system into separate stable cell lines for each component, the patent ensures that each component is expressed at consistent, optimized levels. This eliminates the variability inherent in transient transfection where expression levels of multiple plasmids can differ significantly, thereby improving product quality consistency.
Solution Approach 2:
Instead of introducing multiple plasmids into cells transiently (the conventional approach), the patent inverts the approach by integrating the necessary genetic elements into the genome of stable cell lines. This inversion ensures that the components are always present and expressed at consistent levels, eliminating batch-to-batch variability.
3Productivity
If AAV Rep protein and adenoviral helper proteins are constitutively expressed, then rAAV virion production is continuous, but host cell toxicity increases
Solution Approach 1:
The patent applies dynamics by using inducible promoters (such as tetracycline-responsive promoters) to control the expression of Rep/Cap and helper proteins. This allows the system to dynamically adjust expression levels based on production needs, enabling continuous production capability while minimizing toxicity by keeping expression off when not needed and inducing it only during production phases.
Solution Approach 2:
The patent implements periodic action through inducible expression systems that allow Rep/Cap and helper proteins to be expressed only during specific production periods. By periodically inducing expression in response to tetracycline or its derivatives, the system achieves continuous production capability while limiting exposure time to toxic proteins, thereby reducing host cell toxicity.
Data Source
AI summary
Described herein are polynucleotide constructs and stable cell lines for inducible production of rAAV virions within which are packaged a payload polynucleotide.